
	Where results make sense

Topic: Argatroban

In the News (Thu 24 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Argatroban
		Argatroban is an anticoagulant that is a small molecule direct thrombin inhibitor.
		In 2000, argatroban was licensed by the FDA for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
		Argatroban is metabolized in the liver and has a half life of about 50 minutes.
	www.mrsci.com /Hematology/Argatroban.php (111 words)

	Consumer Drug Information Sheet: Argatroban
		Argatroban is used to treat and reduce the risk of blood clots in patients who have had a reaction to heparin that resulted in reduced platelets and associated blood clots.
		Argatroban is also used in patients undergoing certain heart procedures such as percutaneous coronary interventions (PCI) who are at risk or have had a reaction to heparin that resulted in reduced platelets and associated blood clots.
		Argatroban should not be given to individuals who have major bleeding.
	www.fda.gov /cder/consumerinfo/druginfo/argatrob.HTM (232 words)

	Frequently Asked Questions About Argatroban
		Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35.
		Argatroban does not interact with or induce heparin-dependent antibodies and is thus an appropriate alternative for HIT patients, including those heparin-sensitive patients with coronary artery disease who require PCI.
		Argatroban should be used with extreme caution in disease states and other circumstances in which there is an increased danger of hemorrhage.
	www.argatroban.com /argatroban_faqs.htm (2229 words)

	Argatroban and Bivalirudin : Rx Update: Virtual Hospital (Site not responding. Last check: 2007-10-08)
		Argatroban (GlaxoSmithKline) is an anticoagulant indicated for the prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).
		Argatroban is a synthetic, reversible direct inhibitor of thrombin.
		Argatroban is administered as a continuous intravenous infusion.
	www.healthcare.uiowa.edu /pharmacy/RxUpdate/2002/12rxu.html (440 words)

	Novastan Online, Description, Chemistry, Ingredients - Argatroban - RxList Monographs
		Argatroban is a synthetic direct thrombin inhibitor derived from L- arginine.
		Argatroban is a white, odorless crystalline powder that is freely soluble in glacial acetic acid, slightly soluble in ethanol, and insoluble in acetone, ethyl acetate, and ether.
		Argatroban is available in 250-mg (in 2.5-mL) single-use amber vials, with gray flip-top caps.
	www.rxlist.com /cgi/generic2/argatroban.htm (171 words)

	SECTION 5: Argatroban (Novastan) Protocol
		Argatroban is a synthetic direct thrombin inhibitor that may be chosen as an alternate anticoagulant for patients that are heparin-intolerant, including those with congenital and acquired ATIII deficiencies, those with heparin-induced thrombocytopenia (HIT) and those with high levels of polymorphonuclear granulocyte elastase.
		As argatroban prevents heparin-induced platelet aggregation, it is effective for use as a therapeutic anticoagulant.
		The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.
	www.midwestheartsurgery.com /perf/sec5-3argatroban.htm (736 words)

	Anticoagulant Therapy-Argatroban (via CobWeb/3.1 planetlab2.tamu.edu) (Site not responding. Last check: 2007-10-08)
		Argatroban is the ONLY direct thrombin inhibitor indicated for both prophylaxis and treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT).
		Argatroban is the ONLY indicated anticoagulant in patients with or at risk for HIT undergoing percutaneous coronary intervention PCI.
		Argatroban should be used with extreme caution in disease states or other circumstances in which there is an increased risk of hemorrhage.
	www.argatroban.com.cob-web.org:8888 (307 words)

	Study Results Demonstrate Argatroban Was Well Tolerated in End-Stage Renal Disease Patients Undergoing Hemodialysis
		Argatroban is the only DTI indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT), an immune-mediated reaction to heparin that can lead to serious consequences including limb loss, stroke, and death.
		In contrast, Argatroban is primarily metabolized by the liver; therefore, in patients with moderate to severe kidney dysfunction, Argatroban continues to be excreted normally.
		Argatroban is the only DTI that is not renally cleared and is predominantly hepatically metabolized, which is particularly important and potentially beneficial for patients with ESRD undergoing hemodialysis.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-17-2003/0002059302&EDATE= (2269 words)

	Argatroban Approved For Prevention Or Treatment Of Thrombosis In Heparin-Induced Thrombocytopenia (Site not responding. Last check: 2007-10-08)
		Argatroban blocks the activity of thrombin, a key factor in blood clotting.
		Argatroban’s safety and efficacy were demonstrated in two multicenter, prospective, open-label, historically-controlled, clinical trials.
		Argatroban also resulted in adequate anticoagulation in more than 75 percent of patients within 3-5 hours of the initiation of therapy.
	www.pslgroup.com /dg/1d8462.htm (764 words)

	HIT Resource Center: Articles (Site not responding. Last check: 2007-10-08)
		Manipulation of the level of anticoagulation by giving an additional bolus of argatroban or decreasing the rate of infusion was uncommon and most patients achieved the target activated clotting time (ACT) promptly with the first bolus and infusion.
		Argatroban is metabolized by the liver, however, so patients with significant hepatic dysfunction should generally not receive the drug.
		Therefore, patients with an international normalized ratio (INR) of 4.0 on a combination of warfarin and argatroban may have a lower biologic or bleeding risk than those with a similar INR on warfarin monotherapy.
	www.meetingcast.com /hit/index.php3?l=cohen (581 words)

	Biotechnology News and Information Portal, biotech jobs and career resources Resources.
		The dosing algorithm\r\nutilized in ARGIS in stroke patients differs from dosing of Argatroban in FDA\r\napproved indications.Argatroban, a synthetic direct thrombin inhibitor, was considered to be a\r\npotential treatment option for stroke and was used in the trial because of its\r\naction on thrombin, a protein essential for blood coagulation and clot\r\nformation.
		Argatroban also inhibits fibrin formation, platelet\r\naggregation, and vascular contraction induced by thrombin.About ArgatrobanIn the United States, Argatroban is indicated as an anticoagulant for\r\nprophylaxis or treatment of thrombosis in patients with heparininduced\r\nthrombocytopenia HIT, a serious immune reaction to heparin.
		Argatroban, a synthetic direct thrombin inhibitor, was considered to be a potential treatment option for stroke and was used in the trial because of its action on thrombin, a protein essential for blood coagulation and clot formation.
	www.bioexchange.com /news/news_page.cfm?id=16472 (1873 words)

	No Effect of Clot Age or Thrombolysis on Argatroban's Inhibition of Thrombin -- Hantgan et al. 92 (6): 2064 -- Blood
		for clots permeated with 100 µmol/L argatroban (Fig 4).
		In each case, argatroban (0 to 65 µmol/L) was added to the wells and incubated for an additional 30 minutes before the addition of substrate S-2238 and determination of thrombin activity (as described in the legend to Fig 5).
		± 1.0 µmol/L) and that argatroban inhibited 85% ± 6% of the thrombin
	www.bloodjournal.org /cgi/content/full/92/6/2064 (7376 words)

	Type II Heparin-Induced Thrombocytopenia: New Treatment Options
		Argatroban is a racemic mixture with the S-isomer having twice the antithrombotic activity.
		Since argatroban is predominantly metabolized in the liver, it may be useful in patients with type II HIT who have renal impairment or are on renal replacement therapies.
		Argatroban is contraindicated in patients with active bleeding or known hypersensitivity to the agent.
	www.clevelandclinicmeded.com /medical_info/pharmacy/septoct2001/thrombocytopenia.htm (2320 words)

	Newly Approved Drug Therapies (624): Argatroban Injection, Texas Biotechnology Corporation and SmithKline Beecham
		The conclusion that Argatroban is an effective treatment for heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) is based upon the data from a historically controlled efficacy and safety study (Study 1) and a follow-on efficacy and safety study (Study 2).
		Argatroban is highly selective for thrombin with an inhibitory constant of 0.04 uM.
		Argatroban is capable of inhibiting the action of both free and clot-associated thrombin.
	www.amsect.org /ce/HIT/Argatroban.htm (524 words)

	Anticoagulant Argatroban Available In The United States (Site not responding. Last check: 2007-10-08)
		Argatroban is the first synthetic direct thrombin inhibitor approved for the prophylaxis or treatment of thrombosis in patients with HIT.
		In more than 75 percent of patients treated with argatroban, therapeutic levels of anticoagulation were achieved at first measurement (within three to five hours after initiation of therapy).
		Argatroban is contraindicated in patients with overt bleeding or those with documented hypersensitivity to the product or any of its components.
	www.pslgroup.com /dg/1ea5ea.htm (689 words)

	ENCYSIVE PHARMACEUTICALS
		Argatroban is a synthetic direct thrombin inhibitor that selectively binds to and inactivates thrombin in blood plasma, making it a powerful anticoagulant.
		In 2000, Encysive received U.S. FDA approval of Argatroban for the prevention and treatment of thrombosis in heparin-induced thrombocytopenia (HIT), a condition involving an allergic reaction to heparin and an elevated risk of thrombosis.
		In 2002, Argatroban was approved for use in patients undergoing percutaneous coronary intervention (PCI) with, or at risk of developing, HIT.
	www.encysive.com /faqs.html (184 words)

	News - FDA Approves New Indication For Argatroban, Now For Patients With Or At Risk For Heparin-Induced Thrombocytopenia
		Argatroban is currently approved for the prophylaxis or treatment of thrombosis in patients with HIT.
		Results from the trials indicate that of the 91 patients treated with Argatroban, 98 percent had adequate anticoagulation, and acute procedural success was achieved in 98 percent of Argatroban-treated patients versus 94 percent in the control group.
		The initial FDA approval of Argatroban was based on data from clinical trials showing significantly improved outcomes for patients with or at risk for HIT with or without thrombosis.
	www.docguide.com /news/content.nsf/news/8525697700573E1885256B96005C528F?OpenDocument&c=&count=10&id=48DDE4A73E09A969852568880078C249 (789 words)

	Hem/Onc Today: In heparin-induced thrombocytopenia, argatroban near approval
		Argatroban is a synthetic direct thrombin inhibitor that prevents clot formation.
		Research continues into use of argatroban following angioplasty or in the hemodialysis population, although this is not included in the proposed label, McWilliams said.
		HIT is caused by a complex immune reaction characterized by a strong tendency to clot that puts the patient at risk of major complications, such as myocardial infarction and stroke.
	www.hemonctoday.com /200005/mcwilliams.asp (441 words)

	Pharmacy Times Web CE: New Drugs of 2000
		Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or thrombin-induced reactions (ie, fibrin formation, activation of coagulation factors V, VIII, and XIII, protein C, and platelet aggregation).
		Argatroban is capable of inhibiting the action of both free- and clot-associated thrombin.
		Argatroban is indicated for use as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
	secure.pharmacytimes.com /lessons/html/ndrugs2000.htm (9759 words)

	Argatroban
		Argatroban is a synthetic direct thrombin inhibitor derived from L-arginine indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
		Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.
		However, if Argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the aPTT to decrease prior to initiation of Argatroban therapy.
	www.mongabay.com /health/medications/Argatroban.html (686 words)

	Argatroban
		Argatroban is commonly continued during the initiation of warfarin therapy to assure anticoagulation and to protect against possible transient hypercoagulability.
		Patients receiving >2 mcg/kg/minute of argatroban: Reduce dose of argatroban to 2 mcg/kg/minute; measure INR for argatroban and warfarin 4-6 hours after dose reduction; argatroban therapy can be stopped when the combined INR on warfarin and argatroban is >4.
		As with all anticoagulants, bleeding is a potential adverse effect of argatroban during dental surgery.
	www.musc.edu /pharmacyservices/Drugs/A/Argatroban.htm (1402 words)

	Argatroban in combination with rt-PA in ischemic stroke
		Its molecular weight is 526.66.' Argatroban consists of a mixture of R and S stereoisomers at a ratio of approximately 65:35 (+/- 2%).
		Results of studies by Tanaka, et al, suggest that Argatroban directly inhibits secondary microthrombus formation in acute stages of ischemic strokes An explanation offered by Tamao and Kikumoto describes the mode of action of Argatroban in cerebral thrombosis as an inhibition of the local thrombin formed due to ischemic tissue damage.
		Because the action of local thrombin inhibition halts and possibly reverses microthrombi occlusion, Argatroban could potentially prove to be of benefit in the treatment of strokes classified as large-artery atherosclerotic, acute cardioembolic, and small-artery occlusion (lacunar infarcts).
	research.uth.tmc.edu /nih/Grotta3.htm (373 words)

	ARGATROBAN - INJECTABLE
		USES: Argatroban is a type of "blood thinner" used to help prevent blood clotting that occurs during certain heart conditions (e.g., acute coronary syndrome) or medical procedures (e.g., percutaneous coronary intervention-PCI).
		Argatroban works by inhibiting the protein (thrombin) in the body that helps blood clot.
		Argatroban has been used effectively in combination with certain other "blood thinners" such as aspirin or warfarin.
	www.personalmd.com /drgdb/1271.htm (653 words)

	Anticoagulant Therapy-Argatroban
		Argatroban Injection is a synthetic direct thrombin inhibitor that does not interact with heparin antibodies.
		Argatroban is indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia.
		Argatroban is indicated as an anticoagulant in patients with or at risk for thrombocytopenia undergoing percutaneous coronary intervention (PCI).
	www.argatroban.com /about_argatroban.htm (227 words)

	Argatroban - Drugs & Vitamins - Drug Library - DrugDigest
		ARGATROBAN is an anticoagulant, sometimes called a blood thinner, that is used in the hospital setting.
		Argatroban is for injection or infusion into a vein in the hospital setting.
		If you are going to have surgery, tell your prescriber or health care professional that you have received argatroban.
	www.drugdigest.org /DD/DVH/Uses/0,3915,7848\|Argatroban,00.html (399 words)

	Influence of Lepirudin, Argatroban, and Melagatran on Prothrombin Time and Additional Effect of Oral Anticoagulation -- ...
		Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
		The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used.
		Argatroban and inhibition of the vasomotor actions of thrombin.
	www.clinchem.org /cgi/content/full/48/10/1791 (2093 words)

	ENCYSIVE PHARMACEUTICALS
		Argatroban (FDA approved) Argatroban is a shining example of the strength of our research and development capabilities, as well as our FDA experience.
		The data generated during clinical trials was strong and after navigating the requisite series of FDA hurdles, Argatroban received FDA approval in June 2000.
		In part due to these efforts, Argatroban exceeded its quarterly and yearly sales goals, bringing in over $3 million to Encysive that we used to offset our development expenses for sitaxsentan.
	www.encysive.com /products.html (679 words)

Try your search on: Qwika (all wikis)